Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension

STATUS

Recruiting
participants needed

120
sponsor

Royal Perth Hospital

Send

Updated on 19 February 2024

See if I qualify

body mass index

hypertension

amlodipine

ace inhibitor

amlodipine 5 mg

moxonidine

Summary

This study is designed to investigate whether sympathoinhibition with moxonidine could provide added metabolic benefit compared to the second line therapy in the current guidelines.

Description

This is a randomised, double-blind, cross-over study. Participants will be randomly assigned to receive either moxonidine 0.4mg daily or amlodipine 5mg and will later receive the alternate treatment.

Comprehensive testing will occur after each 12 week treatment phase and will include assessment of muscle sympathetic nerve activity, gut microbiome analysis and metabolic markers.

Details

Condition	Vascular Diseases, Vascular Diseases, Hypertension, Obesity, Obesity
Age	25years - 65years
Treatment	Moxonidine 0.4 MG, Amlodipine 5mg
Clinical Study Identifier	NCT04474899
Sponsor	Royal Perth Hospital
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Age: 25 -65 years
	(Body Mass Index) BMI30kg/m2
	Currently weight stable (+/- 3% in previous 6-12 months and not on any specific exercise or dietary program)
	Elevated clinic systolic (Blood Pressure) BP 135 or diastolic BP 85mmHg
	on ACE inhibitor for at least 6 weeks prior to baseline assessment
Exclusion Criteria
	Grade 2-3 hypertension (systolic office BP >160, diastolic office BP >100 mmHg)
	Secondary causes of hypertension
	CKD (Chronic kidney disease) stage 4-5 {(estimated glomerular filtration) eGFR<30ml/min}
	Heart failure NYHA (New York Heart Association) class II-IV
	Recent CV (cardiovascular) event (acute myocardial infarction, acute coronary syndrome, stroke or transient ischaemic attack within the previous six months) unstable psychiatric condition
	medication such as corticosteroids, several antidepressants and antipsychotics
	Female participants of childbearing potential must have a negative pregnancy test prior to treatment

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension